Business
AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis
Imsidolimab demonstrated rapid and sustained efficacy with 6 of 8 (75%) generalized pustular psoriasis (GPP) patients achieving the primary endpoint at week 4
About this update from Anaptysbio, Inc.
[{"type":"text","content":"Imsidolimab demonstrated rapid and sustained efficacy with 6 of 8 (75%) generalized pustular psoriasis (GPP) patients achieving the primary endpoint at week 4 and week 16Early reduction of erythema with pustules by 60% at week 1 improved to 94% reduction at week 4 and 98% reduction at week 16Phase 3 GEMINI-1 clinical trial has been initiated subsequent to FDA end-of-Phase 2 meeting and FDA orphan drug designation for the treatment of GPPIn addition to GPP, imsidolimab clinical development to focus on moderate-to-severe acne and moderate-to-severe hidradenitis suppurativa, with Phase 2 top-line data anticipated in these indications during the first and second halves of 2022, respectively SAN DIEGO, Oct. 02, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that week 16 data from the GPP GALLOP Phase 2 trial of imsidolimab, its investigational anti-interleukin-36 receptor (IL-36R) therapeutic antibody, was presented at the 2021 European Academy of Dermatology and Venereology (EADV) Congress. The oral presentation, titled “Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody, in the Treatment of Generalized Pustular Psoriasis: Results from a Phase 2 Trial”, was presented by Dr. Johann Gudjonsson, professor of Dermatology at the University of Michigan. “These promising results demonstrate the potential for imsidolimab in the treatment of GPP patients,” said Dr. Johann Gudjonsson. “GPP is a severely debilitating life-threatening dermatological disease in need of novel therapeutic approaches. I look forward to the advancement of imsidolimab in GPP Phase 3 trials.” “I would like to thank all of the patients, physicians, nurses and clinical research collaborators that helped AnaptysBio conduct the GALLOP clinical trial,” said Dr. Paul Lizzul, chief medical officer of AnaptysBio. “We are pleased to advance development of imsidolimab across GPP, acne and hidradenitis suppurativa going forward.” Study DataKey data available to date from the 8 patients enrolled in the GALLOP trial are as follows: Six of 8 (75%) patients treated with imsidolimab monotherapy achieved the primary endpoint of response on the clinical globa...